18th Jan 2006 07:00
Sinclair Pharma PLC18 January 2006 Sinclair Pharma plc Pre-Close Period Trading Update 18 January 2006: Sinclair Pharma plc, the speciality pharma company, provides apre-close period update ahead of its interim results announcement on Tuesday 28March 2006. Sinclair has continued the progress reported for the year ended 30 June 2005with very strong revenue growth and good commercial progress. During theperiod, Sinclair has further developed its product portfolio, obtained EUregistrations for Decapinol toothpaste and gel, launched Atopiclair in the firstEuropean market, Italy, following a successful launch in the US last year, andentered into a number of licensing agreements for its products. Revenues for the six months to 31 December 2005 are expected to be £3.7m,significantly above the £0.8m in the same period last year. This includes afull six month revenue contribution of £1.1m from Sinclair Srl (formerlyEuroderm SpA) which was acquired in January 2005. Chairman Steve Harris said, "It is pleasing to report that the momentum in ourlast financial year continued throughout the first half of the current financialyear. We have continued to see positive progress on all fronts as Sinclairimplements its strategy of becoming an integrated international pharmaceuticalcompany with a broad portfolio of on-market products. Sinclair remainsoptimistic about prospects for the full year and approaches 2006 withconfidence." Enquiries: Sinclair Pharma plc Tel: 01483 426644Dr Michael Flynn, Chief Executive OfficerJerry Randall, Chief Financial Officer Financial Dynamics Tel: 020 7831 3113Ben Atwell / John Gilbert Notes to Editors: Sinclair Pharma plc, based in Godalming in the UK is quoted on the AlternativeInvestment Market (AIM) on the London Stock Exchange and has focused on theacquisition and development of niche patented pharmaceutical products in thefields of oral health and dermatology, and bringing them to the internationalmarket place via out-licensing partners. The Company combines productevaluation, product development, regulatory and business development expertiseto add value to its acquired and in-house developed products. A key element ofthe Sinclair business model is to minimise risk and exposure by avoidinginvolvement in lengthy R&D programmes and rapidly achieving global distributionthrough a network of marketing partners. The Company has already licensed itsproducts for distribution in over 40 countries around the world.www.sinclairpharma.com This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Sinclair Pharma